Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chemical Works of Gedeon RichterRGEDF +2.03%94 Earnings Yield (Joel Greenblatt) % is 18.80% as of Dec. 2025, which is 163% above its 10-year median of 7.14. GuruFocus rates RGEDF with a GF Score™ of 94/100 and a GF Value™ of $35.18 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,010 Drug Manufacturers companies, Chemical Works of Gedeon Richter ranks better than 73.56% on this metric.
Chemical Works of Gedeon Richter's Enterprise Value for the quarter that ended in Dec. 2025 was $4,923 Mil.
Chemical Works of Gedeon Richter's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $481 Mil. Chemical Works of Gedeon Richter's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 18.80%.
The historical rank and industry rank for Chemical Works of Gedeon Richter's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
RGEDF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.64 Med: 7.14 Max: 21.91
Current: 7.77
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Chemical Works of Gedeon Richter was 21.91%. The lowest was 0.64%. And the median was 7.14%.
RGEDF's Earnings Yield (Joel Greenblatt) % is ranked better than 73.56% of 1010
companies
in the Drug Manufacturers industry
Industry Median: 3.375
vs RGEDF: 7.77
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Chemical Works of Gedeon Richter's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 9.73%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Chemical Works of Gedeon Richter (OTCPK:RGEDF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter Earnings Yield (Joel Greenblatt) % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemical Works of Gedeon Richter Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Chemical Works of Gedeon Richter's Earnings Yield (Joel Greenblatt) % falls into.
Chemical Works of Gedeon Richter Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Chemical Works of Gedeon Richter's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $481 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 18.80% mean?
Chemical Works of Gedeon Richter (RGEDF) has a Earnings Yield (Joel Greenblatt) % of 18.80% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Chemical Works of Gedeon Richter and its competitors. This is 163% above median its historical median of 7.14. Over the past decade, Chemical Works of Gedeon Richter's Earnings Yield (Joel Greenblatt) % has ranged from 0.64 to 21.91. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #267 out of 1010 companies in the Drug Manufacturers industry, placing it in the top 26.4%.
Is Chemical Works of Gedeon Richter's Earnings Yield (Joel Greenblatt) % too high?
Chemical Works of Gedeon Richter's current Earnings Yield (Joel Greenblatt) % of 18.80% is 163% above median its 10-year median of 7.14. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 21.91. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.38. Chemical Works of Gedeon Richter's value of 18.80% is 457% above this industry median. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #267 out of 1010 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #267 out of 1010 companies for Earnings Yield (Joel Greenblatt) %. This puts Chemical Works of Gedeon Richter in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.38. Chemical Works of Gedeon Richter's value of 18.80% is 457% above this benchmark. Historically, Chemical Works of Gedeon Richter's own Earnings Yield (Joel Greenblatt) % has ranged from 0.64 to 21.91 over the past decade. While the company's 10-year median is 7.14 vs. the industry median of 3.38, Chemical Works of Gedeon Richter has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.38, based on 1,010 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemical Works of Gedeon Richter's current Earnings Yield (Joel Greenblatt) % of 18.80% is 457% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Chemical Works of Gedeon Richter and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current Earnings Yield (Joel Greenblatt) % is 18.80%, which is 163% above median its own 10-year median of 7.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Fairly Valued. The stock's GF Value™ is $35.18, compared to a current price of $37.85 — trading 7.6% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 18.80%, which is 163% above median its 10-year median of 7.14 and 457% above the Drug Manufacturers industry median of 3.38. Chemical Works of Gedeon Richter's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current Earnings Yield (Joel Greenblatt) % is 18.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued.
The current stock price of $37.85 is trading 7.6% above its estimated GF Value™ of $35.18.
GuruFocus considers Chemical Works of Gedeon Richter to be Fairly Valued.
Key valuation signals for RGEDF:
Earnings Yield (Joel Greenblatt) %: 18.80% (163% above median its 10-year median of 7.14)
GF Value™: $35.18 vs. price of $37.85 (7.6% above fair value)
Industry Position: 457% above the Drug Manufacturers median (#267 of 1010)
No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemical Works of Gedeon Richter Business Description
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
94GF Score
Get the complete analysis for RGEDF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEDF has been successfully added to your 
